Get started
Work

Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

Year: 2018
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.ijrobp.2017.12.300
Authors: R.L. Ferris, G.R. Blumenschein, J. Fayette, J. Guigay, A.D. Colevas, L. Licitra, K. Harrington, S. Kasper, E.E. Vokes, C. Even, F. Worden, N.F. Saba, LCIglesias Docampo, R.I. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Lynch, L. Li, M. Gillison
Institutions: UPMC Hillman Cancer Center, The University of Texas MD Anderson Cancer Center, Centre Léon Bérard, Centre Antoine Lacassagne, Stanford University, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Essen University Hospital, University of Chicago Medical Center, Institut Gustave Roussy, University of Michigan, Winship Cancer Institute, Hospital Universitario 12 De Octubre, Dana-Farber/Harvard Cancer Center, University Hospital Zurich, Kobe University Hospital, National Cancer Center Hospital East, Bristol-Myers Squibb (United States)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2789660370
FWCI: 0.842
Cites:
Cited by: 16
Related to: 10